Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results
  • Inhaled corticosteroids: pneumonia

    Physicians should remain vigilant for pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with chronic obstructive pulmonary disease who are treated with inhaled products that contain s…

    • Therapeutic area: Respiratory disease and allergy
    • Published:
  • Long-acting β2-agonists: reminder for use in children and adults

    Benefits of these medicines used in conjunction with inhaled corticosteroids (ICS) in the control of asthma symptoms in children outweigh any apparent risks.

    • Therapeutic area: Respiratory disease and allergy
    • Published:
  • Inhaled medicines containing corticosteroid

    Licensed doses and differences in potency between different inhaled corticosteroids; advice for use with spacer device.

    • Therapeutic area: Respiratory disease and allergy
    • Published:
  • Review on long-acting β2 agonists for asthma

    Long-acting β2 agonists (LABA) should only be prescribed in conjunction with inhaled corticosteroids for the treatment of moderate to severe asthma.

    • Therapeutic area: Respiratory disease and allergy
    • Published:
  • Letters and medicine recalls sent to healthcare professionals in June 2024

    A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.

    • Therapeutic area: Dermatology and 10 others
    • Published:
  • Long-acting β-agonists: use in chronic obstructive pulmonary disease

    Overall benefits of long-acting β-agonists (LABAs) in the treatment of chronic obstructive pulmonary disease (COPD) continue to outweigh any risks.

    • Therapeutic area: Respiratory disease and allergy
    • Published: